Who are Clofarabine VP 16 ciclophospahamide's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/clofarabine-vp-16-ciclophospahamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Clofarabine VP 16 ciclophospahamide — Competitive Intelligence Brief

Clofarabine VP 16 ciclophospahamide (Clofarabine VP 16 ciclophospahamide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog and alkylating agent. Area: Oncology.

phase 2 Nucleoside analog and alkylating agent Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Clofarabine VP 16 ciclophospahamide (Clofarabine VP 16 ciclophospahamide) — Istituto Giannina Gaslini. Clofarabine VP 16 and cyclophosphamide work by interfering with DNA synthesis and function, leading to cell death in rapidly dividing cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clofarabine VP 16 ciclophospahamide TARGET	Clofarabine VP 16 ciclophospahamide	Istituto Giannina Gaslini	phase 2	Nucleoside analog and alkylating agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog and alkylating agent class)

Istituto Giannina Gaslini · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clofarabine VP 16 ciclophospahamide — Competitive Intelligence Brief. https://druglandscape.com/ci/clofarabine-vp-16-ciclophospahamide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab